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Background. Renal anemia is an important determinant for
left ventricular hypertrophy in dialysis patients and an inde-
pendent prognosis parameter for the cardiovascular survival in
dialysis patients. In addition, an autonomic dysfunction is asso-
ciated with the uremic state and influences the cardiovascular
risk in patients with end-stage renal disease (ESRD).
Methods. We investigated in this prospective longitudinal
study the effect of hemoglobin normalization by a chronic treat-
ment with recombinant human erythropoietin (rhEPO) on car-
diovascular prognosis parameters in 23 patients on chronic
hemodialysis with renal anemia (hemoglobin concentration
≤10.5 g/dL) and echocardiographically proven left ventricu-
lar hypertrophy. We studied muscle sympathetic nerve activity
measured by microneurography; cardiopulmonary baroreflex
activity by lower-body negative pressure (LBNP−) testing; left
ventricular structure and mass index (LVMI) by echocardiogra-
phy; blood pressure by 24-hour readings; peripheral blood flow
and vascular resistance by plethysmography before (U1) and
after 7 months of chronic rhEPO treatment (U2).
Results. In the anemic state, mean (± SD) muscle sympathetic
nerve activity in ESRD was elevated (U1 rest, 34 ± 13 bursts
per minute) and cardiopulmonary baroreflex response during
LBNP markedly lacking (U1 –15 mm Hg, 34 ± 13 bursts per
minute) reflecting a severely impaired autonomic function. Nor-
malization of the hemoglobin concentration by chronic rhEPO
treatment (U1, 10.5 ± 0.9 g/dL versus U2, 13.4 ± 3.1 g/dL, P <
0.001) did not influence sympathetic nerve activity (U2, 34 ± 15
bursts per minute, NS) and cardiopulmonary baroreflex sensi-
tivity did not change (U2 –15 mm Hg, 37 ± 16 bursts per minute,
NS). LVMI decreased significantly after chronic treatment with
rhEPO (U1, 134 ± 26 g/m2 versus U2, 97 ± 25 g/m2, P < 0.001)
and left ventricular geometry developed from an asymmetric to
a symmetric configuration (U1, relative wall thickness 0.58 ver-
sus U2, 0.43, P < 0.001). Under treatment with rhEPO, 24-hour
systolic and diastolic blood pressure did not increase (systolic
U1, 132 ± 4 mm Hg versus U2, 128 ± 3 mm Hg, NS, and di-
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astolic U1, 76 ± 2 mm Hg versus U2, 73 ± 2 mm Hg, NS).
Peripheral blood flow (U1, 6.1 ± 3.3 mL/100 mL/min versus
U2, 6.2 ± 0.6 mL/100 mL/min, NS) as well as forearm vascular
resistance (U1, 15.7 ± 3.3 mm Hg/mL/100 mL versus U2, 14.9 ±
3.1 mm Hg/mL/100 mL, NS) did not change by chronic rhEPO
treatment.
Conclusion. NormaIization of hemoglobin by chronic rhEPO
treatment in dialysis patients has beneficial cardiovascular ef-
fects with regression of left ventricular hypertrophy and im-
provement of left ventricular geometry. However, a reduction
of sympathetic overactivity or a resetting of baroreceptor sensi-
tivity by a rhEPO treatment in dialysis patients in the medium-
term could not be demonstrated. The reason for this may be
the complex and multifactorial pathomechanism of autonomic
dysfunction and cardiovascular disease in ESRD.
The enormous cardiovascular morbidity and prema-
ture mortality in patients with end-stage renal disease
(ESRD) is due to several risk factors which are associated
with the uremic state [1–3]. Of those, an increased sympa-
thetic nerve activity has been recognized as an important
pathomechanism causing cardiovascular complications in
dialysis patients [3]. A sympathetic overactivity is an im-
portant pathogenetic factor for blood pressure elevation
in renal insufficiency and for left ventricular hypertro-
phy (LVH) which is itself an independent determinant
of survival in dialysis patients [4–6]. There is consistent
evidence that a high sympathetic tone predicts mortality
in dialysis patients [3]. Physiologically, an important con-
tributor to the control of the sympathetic outflow is the
cardiopulmonary baroreflex [7]. Yet, the effects of the au-
tonomic dysfunction in the state of chronic renal failure
on the cardiopulmonary baroreflex control are not clear.
It has been suggested that renal anemia stimulates sym-
pathetic nerve activity due to peripheral hypoxia [8, 9].
Correction of renal anemia by the use of recombinant
human erythropoetin (rhEPO) has been proven to be
an effective treatment with several beneficial effects on
exercise capacity, reduction of left ventricular mass and
improvement of cardiac function [10–12]. Retrospective
studies showed a risk reduction of the cardiovascular
mortality by a long-term anemia correction with rhEPO
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[13, 14]. However, beside these beneficial effects, poten-
tial risk factors of a rhEPO treatment have been reported.
In the Normal Haematocrit Trial, Besarab et al [15] stud-
ied the effect of a normal target hematocrit of 42% in
dialysis patients with high cardiac risk (i.e., patients with
ischemic heart disease or congestive heart failure) com-
pared to a target hematocrit of 30%. Based on the interim
results with even a borderline higher mortality in the nor-
mal hematocrit group this study has been aborted pre-
maturely [15]. Therefore, despite of various favourable
effects of a treatment with rhEPO, aiming for a normal
hematocrit level is still a controversial issue in the man-
agement of anemia in renal failure. Beyond this, the de-
velopment or deterioration of arterial hypertension is a
noted complication of the substitution of rhEPO [16]. The
mechanisms of rhEPO to increase blood pressure are not
completely understood. Hemodynamic effects with an in-
creased blood viscositiy may lead to an augmentation of
the total peripheral resistance [17–19]. Whether these
hemodynamic changes during rhEPO therapy are sub-
stantiated in an increased sympathetic activation, which
is an important factor for the cardiovascular prognosis, is
still to be determined.
Therefore, the objectives of our study were to prove
the effects of a long-term treatment with rhEPO on im-
portant cardiovascular prognosis parameters in dialysis
patients. We investigated the sympathetic nerve activity
(measured directly by microneurography) and the au-
tonomic regulation by experimental unloading of car-
diopulmonary baroreceptors before and after chronic
rhEPO substitution. Our other objective was to exam-
ine left ventricular structure and hemodynamic effects of
a chronic rhEPO treatment on blood pressure and pe-
ripheral blood flow in dialysis patients.
METHODS
Study subjects
Twenty-three patients with ESRD were consecutively
enrolled in this prospective longitudinal study. In a
screening phase, a total of 252 patients undergoing
hemodialysis at 3 centers were screened for inclusion and
exclusion criteria. Inclusion criteria were the presence of
a renal anemia, defined as a blood hemoglobin concen-
tration before a dialysis session of ≤10.5 g/dL and a LVH,
assumed by an echocardiographically proved thickening
of interventricular septum (IVS) and left ventricular pos-
terior wall (PW) >12 mm, respectively. Iron deficiency
and other reasons for anemia had to be excluded. Fur-
ther exclusion criteria were the presence of a manifest
peripheral polyneuropathy, occlusive arterial disease, a
history of a malignant tumor, or a thrombosis. Twenty of
the 23 patients were already receiving rhEPO before en-
rollment. All patients gave written informed consent. The
study protocol was approved by the Ethical committee of
the University of Erlangen-Nuremberg.
Study protocol
After enrollment, substitution of rhEPO was stopped
for at least 14 days in all patients. After this EPO-free
interval, baseline examinations of the study parameters
were performed (U1). The following parameters were
determined at U1: sympathetic nerve activity (SNA)
analyzed by microneurography at rest and during
cardiopulmonary baroreflex testing, echocardiographic
measurements, systolic and diastolic blood pressure by
24-hour ambulatory blood pressure readings, peripheral
blood flow by venous occlusion plethysmography, and
laboratory tests (EPO and noradrenaline plasma levels).
The patients were studied on a day between two dialy-
sis sessions. One day before U1, predialysis concentra-
tion of hemoglobin and hematocrit were measured at
the patient’s dialysis center. Subsequently, all patients
received doses of EPO beta (rhEPO) to achieve and
maintain hemoglobin concentrations of ≥12.5 g/dL over
a time period of at least 5 months. Fourteen patients re-
ceived rhEPO intravenously, in nine patients rhEPO was
administered subcutanously. Application frequency was
three times a week in all patients. According to the Eu-
ropean Best Practice Guidelines for the management of
anemia in patients with chronic renal failure [20], the ini-
tial dose of rhEPO was determined as 50 to 150 U/kg
per week. Doses of rhEPO were augmented by 25% of
the baseline dose if the hemoglobin concentration had
not increased by at least 0.7 g/dL during a treatment
period of 2 weeks. If the hemoglobin concentration in-
creased by more than 2.5 g/dL in a 4-week period under
treatment, the dose of rhEPO was reduced by 25%. Iron
status (including serum ferritin concentration and serum
transferrin saturation) was monitored according to [20]
and iron substituted if indicated. After achieving the tar-
get hemoglobin of ≤12.5g/dL, tests of the hemoglobin
concentration and hematocrit were performed every
2 weeks and doses of rhEPO modificated to maintain the
target hemoglobin concentration. After a time period of
at least 5 months with maintained correction of anemia by
rhEPO, measurements of all study parameters were re-
peated (U2). One day before U2, predialysis concentra-
tion of hemoglobin and hematocrit were performed at the
patient’s dialysis center. During the whole study period,
antihypertensive medication was retained and adjusted
according to clinical indication. Dialysis dose remained
unchanged in all subjects during the study period. Throm-
botic complications as arteriovenous shunt thrombosis or
embolism did not occur.
Recordings of SNA
Multiunit recordings of postganglionic SNA were ob-
tained by unipolar tungsten microelectrodes inserted se-
lectively into muscle-nerve fascicles of the peroneal nerve
posterior to the fibular head by the microneurographic
834 Frank et al: Erythropoietin and cardiovascular prognosis
technique of Vallbo et al [21]. The electrodes were con-
nected to a preamplifier, and the nerve signal was fed
through a bandpass filter and routed through an ampli-
tude discriminator to a storage oscilloscope and loud-
speaker and recorded by a polygraph. The recording
of sympathetic activity was considered acceptable when
the neurogram revealed spontaneous, pulse-synchronous
bursts of neural activity, with the largest bursts showing a
minimal signal-to-noise ratio of 3:1. In each study we con-
firmed that sympathetic outflow to skeletal muscle rather
than sympathetic discharge to skin is recorded by demon-
strating that the neural activity did not change in response
to arousal stimuli or a pinch of the skin but showed a char-
acteristically biphasic response to the Valsalva maneuver
[22]. For analysis, sympathetic bursts were identified by
inspection of the filtered and mean-voltage neurograms.
The rate of sympathetic nerve discharge was expressed
as the number of bursts per minute (burst frequency).
SNA was also corrected for the heart rate and expressed
as bursts per 100 heartbeats (burst incidence) [23]. All
nerve recordings were analyzed by two independent in-
vestigators who were unaware of the study protocol. The
data on the SNA given in this study represent the mean
for the two observers. All patients were studied between
1:00 p.m. and 5:00 p.m. without sedation on a day between
two dialysis sessions. The studies were performed with the
patient supine in a calm room with a temperature of 23
to 25◦C.
Testing of cardiopulmonary baroreflex function
by the lower body negative pressure test
Unloading of cardiopulmonary baroreceptors by re-
duction of left ventricular preload leads to an increased
sympathetic efferent outflow to the effector organs heart,
kidneys, and resistance vessels [24]. To assess the auto-
nomic neural response, a cardiopulmonary baroreflex test
by using the lower body negative pressure (LBNP−) test
was performed [25]. At this, each subject was submit-
ted on a negative pressure device consisting of an air-
tight box in which the lower half of the body, down from
the iliac crests, was enclosed [24]. The subjects remained
in a supine position during the whole study period. The
vacuum in the box was achieved by the use of a stan-
dard vacuum cleaner motor. The level of the vacuum was
continuously measured by a standard mercury manome-
ter connected to the inside of the box. Each subject was
submitted to a level of –5 mm Hg for 2 minutes with a
stepwise enhancement of the lower body negative pres-
sure by further –5 mm Hg subsequently every 2 minutes.
The target level of LBNP amounted to –15 mm Hg. Each
LBNP− level was achieved within 2 seconds. SNA was
measured by microneurography under steady-state con-
ditions. Symptoms as syncope or vertigo did not occur.
Echocardiographic studies
Two-dimensional echocardiography was performed
with an ultrasonoscope (Picker-Hitachi CS 192) with a
3.5 MHz probe. Echocardiograms were recorded at rest
in the third or fourth intercostal space lateral to the left
sternal border with the patient recumbent in the supine
or half-sided position. Left ventricular chamber record-
ing was obtained at the tip of the mitral valve leaflet.
To characterize left ventricular structure, measurements
of IVS, posterior wall thickness (PWT), and left ven-
tricular internal end systolic diameter (ESD) as well as
end diastolic (EDD) diameter were performed accord-
ing to the recommendations of the American Society
of Echocardiography (ASE) using the leading edge to
leading edge convention [26]. All parameters were regis-
tered over three cardiac cycles by two independent inves-
tigators and subsequently mean values were calculated.
Left ventricular mass index (LVMI) was calculated con-
formable to the standard formula of Troy, Pombo, and
Rackley [27], which takes both septal and PWT into ac-
count. To avoid overestimation of the “true” left ven-
tricular mass, the values based on the ASE convention
were corrected by the anatomically applying regression
equations of Devereux and Reichek [28]: Left ventricu-
lar mass = 0.8 (ASE cube left ventricular mass) + 0.6 g
(PENN convention). Relative wall thickness (RWT), a
measure of left ventricular geometry, was calculated as:
RWT = (2 PWT/EDD). Concentric hypertrophy was as-
sumed when RWT >0.45 in the presence of LVH and
eccentric hypertrophy as RWT <0.45 in the presence of
LVH, respectively [29].
Laboratory analysis
Blood samples for EPO and noradrenalin plasma levels
were withdrawn into cooled tubes [containing ethylenedi-
aminetetraacetic acid (EDTA) for noradrenaline], imme-
diately centrifuged at 0◦C and stored at –21◦C (EPO) or
–70◦C (noradrenaline), respectively, and analyzed within
3 months of storage. Measurements of EPO plasma lev-
els were performed at the laboratory of the Univer-
sity of Erlangen-Nuremberg using an enzyme-linked im-
munoassay (EPO-Immulite) (Diagnostic Products Cor-
poration, Biermann GmbH, Germany). Plasma nora-
drenaline levels were measured by high-performance liq-
uid chromatography (HPLC) with electrochemical de-
tection (ClinRep) (Recipe Chemicals and Instruments
GmbH, Mu¨nchen, Germany) [30].
Hemodynamic parameters
Twenty-four–hour blood pressure measurements were
achieved by using an automated portable device (Space-
labs Medical, Redmond, WA, USA). The measurements
were carried out every 20 minutes during day time and
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every 30 minutes during night time. Beat-to-beat arte-
rial pressure was taken noninvasively by the validated
method of a photoplethysmographic finger device (Fi-
napres) (Ohmeda, Englewood, CO, USA) [31]. Heart
rate was counted from the electrocardiogram. Forearm
blood flow was measured by the technique of venous oc-
clusion plethysmography with a calibratable mercury-in-
Slastic strain gauge [32]. Measurements were made in
supine position at the forearm contralateral to the ar-
teriovenous fistula of the dialysis patient. The forearm
was positioned at the heart level in 60◦ adduction. A
pneumatic cuff was placed around the upper arm for
venous occlusion. During the phases of venous occlu-
sion the hand was excluded from circulation by inflat-
ing a wrist cuff to suprasystolic pressure. Forearm vascu-
lar resistance was calculated from arterial blood pressure
(measured by Finapres) and forearm blood flow [33].
Statistical analysis
All results are presented as means ± SD. Paired t tests
(two-tailed) were used for the comparisons of study pa-
rameters before and after correction of renal anemia in
dialysis patients. All data were analyzed by using the
SPSS/PC version of the statistics package for social sci-
ences [34]. Statistical significance was indicated by a P
value of less than 0.05.
RESULTS
Patients characteristics are presented in Table 1. The
duration of the study period was 7.9 ± 2.6 months. Causes
for the ESRD were as follows: clinical suspected or
biopsy proven chronic glomerulonephritis (ten patients),
hypertensive nephrosclerosis (five patients), diabetic
glomerulopathy (four patients), interstitial nephritis (two
patients), polycystic kidney disease (one patient), and Al-
port syndrome (one patient). Patients’ concomitant an-
tihypertensive treatment at the beginning of the study
without rhEPO (U1) and after correction of anemia
under chronic substitution of rhEPO (U2) is shown in
Table 2, separately for different antihypertensive drug
classes. Serum creatinine concentrations did not change
significantly (U1 versus U2) (Table 3) and extracellu-
lar fluid volume remained normal in all 23 hemodialysis
patients.
During therapy with rhEPO, the predialytic hemo-
globin concentration increased significantly from 10.5 ±
0.9 g/dL (U1) to 13.4 ± 3.1 g/dL (U2) (P < 0.001)
(Table 3). As well, the hematocrit values increased from
31.4 ± 3.1% (U1) to 40.0 ± 2.6% (U2) (P < 0.001)
(Table 3). Serum levels of EPO increased under substi-
tution of rhEPO significantly from 9.9 ± 6.3 U/L (U1) to
29.9 ± 23.0 U/L (U2) (P < 0.05).
Table 1. Patient characteristicsa
Age years 52.3 ± 14.7
Gender male/female 17/6
Body mass index kg/m2 24.6 ± 3.8
Smoker/non-smoker 8/15
Duration of end-stage renal disease months 42.6 ± 19.8
Dialysis dose hours/week 12.9 ± 0.4
Dose of erythropoietin before the study (20
patients) U/week
3600 ± 650
Dose of erythropoietin during the study U/week 6474 ± 2294
Duration of recombinant human erythropoietin
treatment months
7.9 ± 2.6
aPlus-minus values are mean ± SD.
Table 2. Concomitant antihypertensive medication before (U1) and
after (U2) correction of renal anemia
U1 number U2 number
b blocker 14 13
Angiotensin-converting enzyme inhibitor 14 14
Angiotensin II type 1 receptor antagonist 5 4
Central sympatholytic agent 6 6
Calcium channel blocker 11 12
Diuretics 10 9
Abbreviations are: U1, renal anemia, no therapy of recombinant human
erythropoietin (rhEPO); U2, renal anemia corrected under chronic substitution
of rhEPO.
Table 3. Mean systolic and diastolic blood pressure (determined by
24-hour ambulatory readings), heart rate, peripheral blood flow,
serum creatinine, and noradrenaline plasma levels before (U1) and
after (U2) correction of renal anemia
U1 U2 P value
Mean systolic blood
pressure mm Hg
132 ± 4 128 ± 3 NS
Mean diastolic blood
pressure mm Hg
76 ± 2 73 ± 2 NS
Heart rate beats/min 69 ± 11 66 ± 7 NS
Peripheral blood flow
mL/100 mL/min
6.1 ± 0.7 6.2 ± 0.6 NS
Forearm vascular resistance
mm Hg/mL/100 mL
15.7 ± 3.3 14.9 ± 3.1 NS
Hemoglobin concentration
g/dL
10.5 ± 0.9 13.4 ± 3.1 P < 0.001
Hematocrit% 31.4 ± 3.1 40.0 ± 2.6 P < 0.001
Serum erythropoietin U/L 9.9 ± 6.3 29.9 ± 23 P < 0.5
Serum creatinine mg/dL 9.2 ± 3.4 10.5 ± 2.8 NS
Serum noradrenaline (70 to
750) pg/mL
724.6 ± 140.2 699.3 ± 170.1 NS
Abbreviations are: U1, renal anemia, no therapy of recombinant human
erythropoietin (rhEPO); U2, renal anemia corrected under chronic substitution
of rhEPO.
Effect of anemia correction with rhEPO on SNA
At baseline (U1), muscle sympathetic nerve activity
(MSNA) frequency was 34 ± 4 bursts per minute and
MSNA incidence 48 ± 10 bursts per 100 heartbeats. Af-
ter correction of renal anemia by chronic substitution of
rhEPO, the rate of sympathetic discharge did not change
significantly (U2, MSNA frequency 34 ± 4 bursts per




































Fig. 1. Effect of correction of anemia with chronic recombinant hu-
man erythropoietin (rhEPO) substitution on sympathetic nerve activity
(SNA). (A) Burst frequency. (B) Burst incidence. Abbreviations are:
U1, renal anemia, no therapy of rhEPO; U2, renal anemia corrected
under chronic substitution of rhEPO.
minute; MSNA incidence 51 ± 11, NS) (Fig. 1). A repre-
sentative single microneurographic recording of the ef-
ferent SNA of a hemodialysis patient before and after
correction of renal anemia is shown in Figure 2. As well,
plasma noradrenaline levels did not change before and
after treatment with rhEPO (724.6 ± 140.2 pg/mL (U1)
versus 699.3 ± 170.1 pg/mL (U2), NS) (Table 3).
Effect of anemia correction with rhEPO
on cardiopulmonary baroreflex control
We compared efferent sympathetic nerve activity dur-
ing the unloading of cardiopulmonary baroreceptors us-
ing the LBNP− test at the phase of renal anemia (U1)
and after chronic rhEPO treatment (U2). In compari-
son with normal subjects [26], the response of the SNA
discharge during the stepwise increased levels of lower
body negative pressure was found to be reduced in dial-
ysis patients in the stage of renal anemia (U1 rest, 34 ±
13, NS; U1 LBNP− level, –5 mm Hg, 34 ± 15, NS; U1
LBNP− level, –10 mm Hg, 36 ± 17, NS; and U1 LBNP−
level, –15 mm Hg, 34 ± 13, NS, bursts per minute, re-
spectively) (Table 4). Normalization of the hemoglobin
concentration by chronic rhEPO treatment did not in-
fluence the cardiopulmonary baroreflex response during
U1: MSNA 64 bursts/min
U2: MSNA 65 bursts/min
0 10 20 30 40 50 60
Time, seconds
Fig. 2. Representative single microneurographic recording of the mus-
cle sympathetic nerve activity (MSNA) of a dialysis patient before and
after correction of renal anemia by recombinant human erythropoietin
(rhEPO). Abbreviations are: U1, renal anemia, no therapy of rhEPO;
U2, renal anemia corrected under chronic substitution of rhEPO.
Table 4. Effect of anemia correction by recombinant human
erythropoietin (rhEPO) treatment on the response of the sympathetic
nerve activity (SNA) during cardiopulmonary baroreflex testing in
dialysis patients
−5 mm LBNP− level −15 mm P
Rest Hg −10 mm Hg Hg value
SNA U1
bursts/min
34 ± 13 34 ± 15 36 ± 17 34 ± 13 NS
SNA U2
bursts/min
34 ± 15 35 ± 15 36 ± 17 37 ± 16 NS
Hear rate U1
beats/min
69 ± 11 70 ± 8 70 ± 9 69 ± 10 NS
Heart rate U2
beats/min
67 ± 7 68 ± 8 68 ± 7 66 ± 8 NS
Abbreviations are: LBNP−, lower-body negative pressure; U1, renal anemia,
no therapy of rhEPO; U2, renal anemia corrected under chronic substitution of
rhEPO.
the LBNP− test (U2 rest, 34 ± 15; U2 LBNP− level, –5
mm Hg, 35 ± 15; U2 LBNP− level, –10 mm Hg, 36 ± 17;
and U1 LBNP− level, –15 mm Hg, 37 ± 16, bursts per
minute, respectively, P not significant for all comparisons
at different levels) (Table 4).
Effect of anemia correction with rhEPO
on cardiac structure
At baseline, a LVH (U1 IVS 15.4 ± 2.8 mm; PW 14.1 ±
2.5 mm) as well as an enhanced LVMI (U1 LVMI 134 ±
26 g/m2) was present in all dialysis patients. During treat-
ment with rhEPO, left ventricular septal and PW thick-
ness decreased significantly (U2 IVS 11.9 ± 2.8 mm, P <
0.001; PW 11.1 ± 1.6 mm, P < 0.001) (Fig. 3). As well,
LVMI was reduced significantly after correction of ane-
mia (U2 97 ± 25 g/m2, P < 0.001) (Fig. 4). Left ventricular
ESD and EDD were not enlarged at the beginning of the



























Fig. 3. Effect of anemia correction by chronic recombinant human ery-
thropoietin (rhEPO) treatment on left ventricular septal (IVS) and pos-
terior wall thickness (LVPW). Abbreviations are: U1, renal anemia, no















Fig. 4. Effect of anemia correction by chronic recombinant human ery-
thropoietin (rhEPO) treatment on left ventricular mass index (LVMI).
Abbreviations are: U1, renal anemia, no therapy of rhEPO; U2, renal
anemia corrected under chronic substitution of rhEPO.
study and remained unchanged during the study course
(U1 ESD 35.2 ± 11 mm versus U2 ESD 33.8 ± 5 mm, NS;
U1 EDD 50.1 ± 5.6 mm versus U2 EDD 51.2 ± 4.9 mm,
NS). The RWT, a parameter for the left ventricular ge-
ometry, decreased under chronic treatment with rhEPO
significantly (U1 0.58 versus U2 0.43, P < 0.001) indicat-
ing a remodelling of the eccentric LVH into a symmetric
configuration.
Effect of anemia correction with rhEPO
on hemodynamic parameters
Twenty-four–hour systolic and diastolic blood pressure
were normotensive at U1 and did not change after correc-
tion of renal anemia by rhEPO treatment (U2) (Table 3).
At this, the number and dose of the antihypertensive
drugs did not differ significantly during the study course
(Table 2). Heart rate was normofrequent at the phase
of renal anemia and did not change before and after
the treatment with rhEPO (U1 69 ± 11 beats/min ver-
sus U2 66 ± 7 beats/min, NS). Correction of anemia did
not change forearm blood flow (U1 6.1 ± 0.7 mL/100 mL/
min versus U2 6.2±0.6 mL/100 mL/min, P not significant)
(Table 3). As well, forearm vascular resistance remained
unchanged during rhEPO treatment (Table 3).
DISCUSSION
The main effects of a chronic therapy with rhEPO
in dialysis patients are as follows. Normalization of the
hematocrit level in dialysis patients by a chronic ther-
apy with rhEPO leads to a significant regression of LVH
and also to an improvement of left ventricular geome-
try. SNA which is elevated in ESRD did not decrease
after correction of renal anemia. The impaired cardiopul-
monary baroreflex as a part of the autonomic dysfunction
in dialysis patients did not change after normalization of
the hematocrit level. Under chronic rhEPO treatment,
blood pressure did change significantly and antihyperten-
sive medication was continued. Under these conditions,
changes of the peripheral blood flow during rhEPO treat-
ment in dialysis patients did not occur. These findings
suggest that correction of renal anemia by rhEPO has
beneficial effects on cardiovascular prognosis parameter
such as LVH and geometry. However, the autonomic dys-
function is not reversible by an effective rhEPO therapy
for the medium-term in dialysis patients.
Effect of correction of anemia with rhEPO
on cardiac structure and hemodynamic parameters
LVH, a major cardiovascular risk factor, is present in
74% in patients starting renal replacement therapy [35].
Renal anemia is one important determinant for the de-
velopment of LVH [3]. It has been demonstrated that
effective correction of anemia with rhEPO treatment for
8 months reduces left ventricular mass significantly [3]. In
correspondence to these results, we found that normaliza-
tion of hemoglobin over a time period of 7 months, LVMI
decreased significantly in all patients. Over that, we found
that the configuration of the left ventricle developed from
an asymmetric into a symmetric geometry after correc-
tion of renal anemia. Left ventricular geometry in uremic
patients has been shown to be a strong predictor of cardio-
vascular mortality [36]. Thus, these findings may indicate
that an effective correction of anemia in dialysis patients
has favorable effects beyond the reduction of left ventric-
ular mass with a remodeling of left ventricular geometry
in ESRD.
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Development or deterioration of a preexisting eleva-
tion in diastolic blood pressure is known as a possible side
effect of rhEPO therapy [16]. In our study, 24-hour blood
pressure readings revealed no change of systolic or di-
astolic blood pressure during rhEPO treatment. At this,
dose and number of antihypertensive drugs did not dif-
fer significantly with and without rhEPO therapy. From
a hemodynamic viewpoint, a rapid reversal of anemia-
induced peripheral vasodilatation by a fast increase in
hematocrit with high doses of rhEPO has been presumed
as a factor which may contribute to the hypertensive ef-
fect of rhEPO [37]. In our study, increases of rhEPO doses
were performed carefully striving for a tempered rise of
hemoglobin with a close clinical monitoring of the pa-
tients at their dialysis centers. Thus, in accordance with
previous reports [38], we point out that with a close atten-
tion to patient surveillance, hypertensive problems dur-
ing rhEPO therapy should be treatable.
London et al [39] demonstrated a significant reduc-
tion of forearm blood flow and a significant increase in
limb vascular resistance after correction of renal anemia
in 11 hemodialysis patients. However, in parallel with
our microneurographic findings, the peripheral arterial
blood flow as well as vascular resistance did not change
after correction of anemia in our study. Yet, these results
have to be analyzed carefully, since in ESRD the fluid
balance fluctuates depending on the duration of the
dialysis-free interval. These for the ESRD-specific factors
interact with hemodynamics and blood viscosity render-
ing an interpretation more difficult. Although the “dry”
body weight had formally not changed significantly, a
transient change of hemodynamics early on induced by
the treatment of rhEPO can not be excluded.
Effect of anemia correction with rhEPO on SNA
at rest and during cardiopulmonary baroreflex testing
Converse et al [4] demonstrated a state of sympathetic
overactivity in chronically dialyzed patients with a 2.5
times higher rate of sympathetic nerve discharge com-
pared to normal subjects. The mean rate of sympathetic
nerve discharge was 2.5 times higher in patients receiving
hemodialysis compared to normal subjects [4].
Evaluation of the SNA by the measurement of plasma
catecholamines is insensitive and may be influenced by
many factors such as synaptic transmitter release, re-
uptake mechanisms, and regional blood flow [40]. Be-
sides, ESRD may lead to changes in catecholamine
metabolism and clearance. In contrast, microneurogra-
phy allows a precise, directly intraneural, quantitative,
and reproducible measurement of postganglionic SNA.
In dialysis patients without rhEPO treatment we found
an elevated sympathetic neural vasoconstrictor activity
at rest. Renal anemia may be accounted as one poten-
tial mechanism for the increased SNA in chronic renal
insufficiency. Hypoxia, induced by a significant reduction
of the hematocrit concentration due to the lack of ery-
thropoietin, may lead to a stimulation of the sympathetic
nervous system [9]. An important aim of our study was
to determine the effect of anemia correction by rhEPO
on the autonomic function in dialysis patients. Normal-
ization of the hemoglobin concentration did not alter
the SNA at rest in dialysis patients. The reason for the
lack of decrease of the sympathetic activity despite the
improved oxygen supply after anemia correction may be
due to a stimulation of the afferent nerves of the failing
kidneys which could induce a reflex activation of the ef-
ferent sympathetic discharge. A hint for this hypothesis
is the observation that in patients who had undergone bi-
lateral nephrectomy no excess sympathetic activity could
be documented [7]. As well, experimental denervation of
the renal afferent nerves has been shown to reduce sym-
pathetic discharge and blood pressure in animals [41].
In normal subjects, the SNA increases with age and
is higher in men than in women [42]. With regard to
these results, we found that sympathetic vasoconstrictor
discharge in dialysis patients is higher than in normal
subjects in consideration of age and gender. However,
the extent of sympathetic overactivity in our study pop-
ulation was less than the highly sympathetic activation
in dialysis patients described by Converse et al [7]. The
reason for this may be the fact that in our study 22 of
the 23 study participants received antihypertensive drugs
including ACE inhibitors, angtiotensin II type 1 (AT1)
receptor blockers, b blockers, and sympatholytic agents,
which all may modulate the central sympathetic outflow
[43–46]. In comparison with this, in the study of Con-
verse et al [7] only 50% of the hemodialyzed patients
were treated with antihypertensive medication. Thus, the
more extensive pharmacologic influence in our study may
be the cause for the relatively less sympathetic activation
compared to earlier results.
To assess the baroreflex-mediated control of SNA we
used a challenge maneuver causing a nonhypotensive or-
thostatic stress. In normal subjects, unloading of cardiac
baroreceptors during lower body negative pressure in-
creases sympathetic discharge to skeletal muscle in a po-
tent way [25, 47]. A decreased baroreflex sensitivity has
been proven to be associated with a high cardiovascu-
lar risk [48]. We found a strongly diminished sympathetic
response in the cardiopulmonary baroreflex testing with
a lack of increase in sympathetic efferent discharge in
anemic dialysis patients. These results indicate a severe
autonomic disorder with a markedly reduced baroreflex
sensitivity. Of note, after correction of the renal anemia by
rhEPO treatment for months, the sympathetic response
during the cardiovascular stress was not adequate as well.
Our study is limited by the lack of a crossover design.
Nevertheless, these findings may confirm the suggestion
that autonomic dysfunction in ESRD is a multifactorial
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process at which a number of pathogenetic factors asso-
ciated with renal failure are involved. Beside secondary
organ damage of vessels and heart as LVH and hema-
tologic factors as anemia, uremic toxins may play a role
damaging autonomic nerve fibres causing an impairment
of baroreflex-mediated sympathetic nerve control [49].
Whether correction of renal anemia yet in an earlier stage
of chronic renal failure can prevent or mitigate autonomic
disorders remains to be determined.
CONCLUSION
Normalization of hemoglobin in dialysis patients has
beneficial cardiovascular effects with regression of LVH
and improvement of left ventricular geometry. However,
a reduction of sympathetic overactivity or a resetting
of baroreceptor sensitivity by rhEPO treatment in the
medium-term could not be achieved. The reason for this
may be the complex and multifactorial pathomechanism
of cardiovascular disease and autonomic dysfunction in
ESRD.
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